Merck Signs $1.2 Billion U.S. Supply Pact for Covid-19 Pill (1)

June 9, 2021, 12:54 PM

Merck & Co. entered a $1.2 billion agreement to supply the U.S. government with its pill for Covid-19, should the experimental drug receive regulatory clearance.

Merck agreed to supply 1.7 million courses of the treatment, called molnupiravir, to the U.S., according to a statement Wednesday. Likened to Tamiflu, an antiviral used in the early stages of influenza, the Covid drug is being developed with Ridgeback Biotherapeutics.

While vaccines are reducing the number of new Covid infections, mainly in wealthy countries rolling out large immunization campaigns, doctors need new treatments for those who do get sick. Molnupiravir is in a ...

To read the full article log in.

Learn more about a Bloomberg Law subscription.